Abstract

This study investigated using alpha-particle–emitting ²¹¹At attached to monoclonal antibodies for treating recurrent brain tumors. Eighteen patients received injections of labeled antibodies into surgically created resection cavities. Results showed 96.7% ± 3.6% of ²¹¹At decays occurred in the SCRC, with minimal systemic exposure and no dose-limiting toxicity. Six patients experienced mild neurologic side effects that resolved quickly. Median survival for all patients was 54 weeks, with promising outcomes suggesting this approach is feasible, safe, and associated with promising antitumor benefit in patients with recurrent malignant brain tumors.

Publication Information

Journal: Journal of Nuclear Medicine

Volume: 49, Issue 1

Pages: 30-38

Publication Date: January 2008

DOI: 10.2967/jnumed.107.046938

Journal Link: https://jnm.snmjournals.org/content/49/1/30

Authors

Michael R. Zalutsky, David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, Roger E. McLendon, Terence Z. Wong, Darell D. Bigner

Institutional Affiliation: Duke University Medical Center, Durham, North Carolina, USA

Study Period: April 1998 – June 2001